Physician Perspectives about the US Quality Payment Program: MIPS Benefits and Alternative Payment Model Incentives
Journal of Hospital Management and Health Policy
Authors
Joshua M. Liao, Amol S. Navathe
CHIBE Experts
Research Areas
You might also be interested in...
View all publications-
Measuring Quality-Weighted Hospital-Free-Days in Acute Respiratory Failure: A Modified Delphi Study
Annals of the American Thoracic SocietyMarch 20, 2024 -
Field Testing the Transferability of Behavioural Science Knowledge on Promoting Vaccinations
Nature Human BehaviourMarch 14, 2024 -
Health Care Use Among Patients Retroactively Insured via a Hospital-Based Insurance Linkage Program
Journal of General Internal MedicineMarch 14, 2024 -
The Next Decade of Healthcare
HealthcareFebruary 29, 2024 -
Changes in Health Care Workers' Economic Outcomes Following Medicaid Expansion
JAMAFebruary 27, 2024 -
Health Care Resource Utilization and Costs Associated With Diagnosed Medication Overuse Headache and Potential Acute Medication Overuse in Individuals With Migraine
CephalalgiaFebruary 27, 2024 -
Evaluating the Implementation of a Community Health Worker-Delivered Intervention Integrating Asthma Care in West Philadelphia Public Schools
Journal of AsthmaFebruary 9, 2024 -
Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting
Clinical Lymphoma Myeloma LeukemiaFebruary 8, 2024 -
A Social Network Analysis of Hemodialysis Clinics: Attitudes Towards Living Donor Kidney Transplant Among Influential Patients
Kidney360February 7, 2024 -
Differential Hospital Participation in Bundled Payments in Communities with Higher Shares of Marginalized Populations
Journal of General Internal MedicineFebruary 6, 2024 -
Officer-Involved Killings of Unarmed Black People and Racial Disparities in Sleep Health
JAMA Internal MedicineFebruary 5, 2024 -
Real-World Analysis of Adverse Event Rates After Initiation of Ibrutinib Among Medicare Beneficiaries With Chronic Lymphocytic Leukemia
Cancer MedicineFebruary 1, 2024